CERA

unofficial impact factor 1.46
Search for
Advanced search
Cost Effectiveness and Resource Allocation
Tools
Open Access Highly Access Email this article to a friend

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis

Feng Xie*, Gord Blackhouse, Nazila Assasi, Kathryn Gaebel, Diana Robertson and Ron Goeree

Cost Effectiveness and Resource Allocation 2009, 7:20 doi:10.1186/1478-7547-7-20

Fields marked * are required


Multiple email addresses should be separated with commas or semicolons.